pH-responsive high-density lipoprotein-like nanoparticles to release paclitaxel at acidic pH in cancer chemotherapy by Shin, Jae-Yoon et al.
© 2012 Shin et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of Nanomedicine 2012:7 2805–2816
International Journal of Nanomedicine
pH-responsive high-density lipoprotein-like 
nanoparticles to release paclitaxel at acidic  
pH in cancer chemotherapy
Jae-Yoon Shin1,*
Yoosoo Yang1,*
Paul Heo1
Ji-Chun Lee1
ByoungJae Kong1
Jae Youl Cho1
Keejung Yoon1
Cheol-Su Shin2
Jin-Ho Seo3
Sung-Gun Kim4
Dae-Hyuk Kweon1
1Department of Genetic Engineering, 
College of Biotechnology and 
Bioengineering, and Center for 
Human Interface Nano Technology, 
Sungkyunkwan University, 2APTech 
Research Center, Suwon, 3Department 
of Agricultural Biotechnology, 
Seoul National University, Seoul, 
4Department of Biomedical Science, 
Youngdong University, Chungbuk, 
South Korea
*These authors contributed equally to 
this work
Correspondence: Dae-Hyuk Kweon 
Department of Genetic Engineering, 
College of Biotechnology and 
Bioengineering, and Center for 
Human Interface Nano Technology, 
Sungkyunkwan University, Suwon,  
South Korea 
Tel +82 31 290 7869 
Fax +82 31 290 7870 
Email dhkweon@skku.edu 
 
Sung-Gun Kim 
Department of Biomedical Science, 
Youngdong University,  
Chungbuk 370-701, South Korea 
Tel +82 43 740 1373 
Fax +82 43 740 1299 
Email sgkim@yd.ac.kr
Background: Nanoparticles undergoing physicochemical changes to release enclosed drugs 
at acidic pH conditions are promising vehicles for antitumor drug delivery. Among the various 
drug carriers, high-density lipoprotein (HDL)-like nanoparticles have been shown to be beneficial 
for cancer chemotherapy, but have not yet been designed to be pH-responsive.
Methods and results: In this study, we developed a pH-responsive HDL-like nanoparticle 
that selectively releases paclitaxel, a model antitumor drug, at acidic pH. While the well known 
HDL-like nanoparticle containing phospholipids, phosphatidylcholine, and apolipoprotein A-I, 
as well as paclitaxel (PTX-PL-NP) was structurally robust at a wide range of pH values (3.8–
10.0), the paclitaxel nanoparticle that only contained paclitaxel and apoA-I selectively released 
paclitaxel into the medium at low pH. The paclitaxel nanoparticle was stable at physiological 
and basic pH values, and over a wide range of temperatures, which is a required feature for 
efficient cancer chemotherapy. The homogeneous assembly enabled high paclitaxel loading per 
nanoparticle, which was 62.2% (w/w). The molar ratio of apolipoprotein A-I and paclitaxel was 
1:55, suggesting that a single nanoparticle contained approximately 110 paclitaxel particles in a 
spherical structure with a 9.2 nm diameter. Among the several reconstitution methods applied, 
simple dilution following sonication enhanced the reconstitution yield of soluble paclitaxel 
nanoparticles, which was 0.66. As a result of the pH responsiveness, the anticancer effect of 
paclitaxel nanoparticles was much more potent than free paclitaxel or PTX-PL-NP.
Conclusion: The anticancer efficacy of both paclitaxel nanoparticles and PTX-PL-NP was 
dependent on the expression of scavenger receptor class B type I, while the killing efficacy 
of free paclitaxel was independent of this receptor. We speculate that the pH responsiveness 
of paclitaxel nanoparticles enabled efficient endosomal escape of paclitaxel before lysosomal 
break down. This is the first report on pH-responsive nanoparticles that do not contain any 
synthetic polymer.
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Introduction
Over the past decade, various nanoparticles for drug delivery have been developed 
to target specific cells selectively and to respond to environmental chemical/  physical 
stimuli, such as pH and temperature. Among the various environmental stimuli, 
pH gradients have been widely employed to design novel tumor-targeting drug deliv-
ery systems because the interstitial microenvironment surrounding the solid tumor is 
acidic, which is due to the hypoxia and lactic acid accumulation that occurs in a rapidly 
growing tumor.1–3 The lower extracellular pH in most solid tumors than that in the 
surrounding tissues and blood is now regarded as a phenotype of solid tumor growth 
and invasiveness. The pH sensitivity of a delivery system is also important for killing 
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cancer cells that are not in a solid tumor. Because the pH 
of endosomes or lysosomes in the cytoplasm is acidic, pH 
sensitivity can trigger extensive release of anticancer drugs 
after endocytosis. This selective release of cytotoxic drugs at 
low pH decreases the cytotoxicity and promotes the efficacy 
of chemotherapy.4,5 Consequently, various pH-responsive 
drug delivery systems have been designed to result in physi-
cochemical changes of the carriers in response to low pH and 
release the enclosed drugs at the target site.4,6–9
High-density lipoproteins (HDL) consisting of apolipo-
protein A-I and lipophilic components, such as phospholipids, 
cholesterol, and cholesteryl esters, have been used as drug 
carriers for hydrophobic drugs in cancer chemotherapy.10,11 
HDL has a hydrophobic interior core for the transport of 
cholesterol in vivo, which is favorable for including lipophilic 
drugs. Furthermore, it is able to target cancer cells, because the 
apolipoprotein A-I in HDL is recognized by scavenger receptor 
class B type I (SR-BI), which is overexpressed in most cancer 
cells.12–14 In contrast with artificial emulsifiers, which have been 
reported to cause a number of side effects related to immune 
responses, such as hypersensitivity reactions, nephrotoxicity, 
and neurotoxicity,15 HDL does not trigger an immune response, 
because all components of HDL are endogenous molecules 
that are richly present in the human body. Therefore, many 
lipophilic drugs have been assembled with apolipoprotein A-I 
and phospholipids, which result in the formation of soluble 
HDL-like nanoparticles.10,11 However, despite these beneficial 
characteristics for cancer chemotherapy, HDL have never been 
employed to generate a pH-responsive drug delivery system. 
This is primarily due to the high stability of the HDL-like nano-
particle over a wide range of pH values, which makes it difficult 
for the enclosed drug to be released upon changes in pH.
The stability of HDL is highly correlated with the 
α-helical content of apolipoprotein A-I. An increase in the 
α-helical content of apolipoprotein A-I has been observed 
when apolipoprotein A-I binds amphipathic phospholipids, 
indicating that the interaction between phospholipids and 
apolipoprotein A-I is responsible for the stability of the dis-
coidal structure of HDL.16 However, in the reverse cholesterol 
pathway, an increase in the nonamphipathic cholesterol con-
tent in HDL leads to the conversion of the discoidal structure 
to a spherical structure and destabilization of apolipoprotein 
A-I binding, which results in structural disorder at the HDL 
surface.17 Thus, we hypothesized that exclusion of phospho-
lipids during the assembly of HDL-like nanoparticles may 
result in sensitivity to environmental changes, such as a pH 
decrease, because of the expected disordered structure of the 
HDL in the absence of phospholipids.
All pH-responsive drug carriers developed until now 
consist of synthetic polymers. In this study, we attempted 
to generate a pH-responsive HDL-like nanoparticle using 
only apolipoprotein A-I, which is abundant in the human 
body. Paclitaxel was assembled with only apolipoprotein 
A-I in the absence of phospholipids, and was compared 
with PTX-PL-NP, an HDL-like nanoparticle which contains 
phospholipids as well as paclitaxel and apolipoprotein A-I. 
Indeed, the paclitaxel nanoparticles selectively released 
paclitaxel at low pH, while PTX-PL-NP did not show a 
pH-dependent release profile. The pH-dependent release 
of paclitaxel from the paclitaxel nanoparticles resulted in a 
dramatically enhanced anticancer effect.
Materials and methods
Expression and purification  
of recombinant apolipoprotein A-I
The expression of codon-optimized human apolipopro-
tein A-I was performed using the pET protein expression 
system   (Novagen, Madison, WI), with the previously 
described  expression vector pNFXex-apolipoprotein A-I.18 
  Purification of His-tagged apolipoprotein A-I was performed 
as elsewhere.19
Assembly of HDL-like paclitaxel 
nanoparticles
1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC, 
Avanti Polar Lipids, Alabaster, AL) was prepared as a 25 mM 
stock solution in chloroform, and was dried under a stream 
of nitrogen gas to produce a lipid film on the inner wall of a 
test tube. The glass tube containing the phospholipid film was 
placed in vacuum overnight to remove the residual solvent. 
The film of dried POPC was then dissolved in disc formation 
buffer (10 mM Tris HCl, 100 mM NaCl, pH 7.4) supple-
mented with 100 mM sodium cholate, resulting in a final lipid 
to cholate ratio of 1:4, and was dissolved further at 37°C for 
2 hours to produce full dissolution. Then, 0.1 mL of 1.64 mM 
POPC solution was mixed with an equal volume of 1.4 mg/mL 
(1.64 mM) paclitaxel, which was dissolved in the disc forma-
tion buffer containing 100 mM sodium cholate. To induce 
self-assembly of PTX-PL-NP, the concentration of sodium 
cholate was lowered below its critical micelle concentration 
by diluting the mixture solution with 2 mL disc formation buf-
fer containing purified apolipoprotein A-I. In the final mixture, 
the molar ratio of apolipoprotein A-I to (paclitaxel:POPC) was 
maintained at 1:75. After the protein/lipid aggregates were 
removed by centrifugation at 15,000 rpm for 30 minutes, the 
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supernatant was subjected to size exclusion   chromatography. 
The temperature was maintained at 25°C throughout this 
preparation process. This procedure resulted in a final pacli-
taxel recovery yield of 50%–60%.
While acceptable amounts of PTX-PL-NP could be 
obtained by following a widely employed procedure for 
the HDL-like nanoparticle assembly described above,12,20 
paclitaxel nanoparticles not containing phospholipids could 
not be formed by using the same method. To enhance the 
assembly yield of paclitaxel nanoparticles, we used several 
methods, including dialysis, dilution, thermal treatment, and 
sonication. Of these methods, simple dilution following soni-
cation resulted in a good assembly yield. After size exclusion 
chromatography purification of the paclitaxel nanoparticles, 
about 66% of the initially added paclitaxel was found in these 
nanoparticles, while approximately one third of the paclitaxel 
had precipitated during the assembly process.
Size exclusion chromatography
The assembled nanoparticles were separated by size exclu-
sion chromatography using a Superdex-200 10/300 GL 
column on an ÄCTA FPLC apparatus (GE Healthcare, 
Buckinghamshire, UK). After the column was equilibrated 
with 10 mM Tris HCl (pH 8.0), a 100 µL sample was injected 
into the column at a flow rate of 0.5 mL/minute.
Dynamic light scattering and transmission 
electron microscopy
The size distribution of HDL-like nanoparticles was deter-
mined by a dynamic laser light scattering technique using 
a Dynapro apparatus (Wyatt Technology, Santa Barbara, 
CA). The scattering angle and temperature were fixed at 
90°C and 25°C, respectively. Energy filtered-transmission 
electron microscopy was performed using a LIBRA 
120 electron microscope (Carl Zeiss, Jena, Germany). After 
deposition of the HDL-like nanoparticles onto a 100 mesh 
copper grid coated with carbon, the grid was tapped to a 
filter paper to remove surface water and negatively stained 
using 2% uranyl acetate. The samples were air-dried before 
the measurements were performed.
Quantitative assay of paclitaxel
Paclitaxel was quantified using a high-pressure liquid 
chromatography apparatus equipped with a Capcell Pak 
C18 MG reversed-phase column (Shiseido, Tokyo, Japan) 
and an ultraviolet detector. To extract paclitaxel from the 
paclitaxel nanoparticles or the PTX-PL-NP, 1 mL hexane: 
n-propanol (5:3) was added to a 1 mL sample and mixed 
vigorously for 15 minutes. The solvent was removed using 
nitrogen gas purging after centrifugation and collection of 
light   solution. Dried paclitaxel was dissolved with absolute 
ethanol and injected into the high pressure liquid chromatog-
raphy   apparatus. Pure ethanol was used as an isocratic mobile 
phase at a flow rate of 1.0 mL/minute. The concentration of 
paclitaxel was quantified from a standard curve.
Time-dependent uncoating  
of apolipoprotein A-I shell  
from nanoparticles
Release of paclitaxel from the nanoparticles was observed 
using a static light scattering assay. Static light scattering 
measures time-averaged intensity of scattered light which 
is proportional to the size of the macromolecule when the 
concentration is fixed. Thus, the decrease in light scattering 
intensity resulting from disassembly of nanoparticles to free 
paclitaxel and free apolipoprotein A-I, which is accompa-
nied by a size decrease, and revealed by both size exclusion 
chromatography and dynamic laser light scattering, could 
be a good measure of paclitaxel release from the paclitaxel 
nanoparticles. Static light scattering was measured using a 
Molecular Device SpectraMax M2 fluorometer at an excita-
tion and emission wavelength of 500 nm. After reading the 
value for 2 hours at the same pH (7.4), the pH values of the 
samples were lowered or increased to designated pH values 
(designated to 0), and the light scattering intensity was further 
recorded for another 6 hours. The plotted data were averaged 
from three independent experiments.
Circular dichroism analysis
Circular dichroism measurements were carried out using an 
automated Jasco Model CD spectrometer. The spectra were 
measured wavelengths ranging from 240 to 190 nm at room 
temperature, using a 1 mm path length cell. The background 
circular dichroism spectrum of paclitaxel and/or phospholipid 
was subtracted from that of the nanoparticles to obtain the 
apolipoprotein A-I spectrum in the cognate nanoparticles.
Cell lines and culture
MCF-7, SK-Br-3, and MDA-MB-231 breast cancer cell lines 
were obtained from the American Type Culture Collection. 
MCF-7 and MDA-MB-231 cell lines were maintained in 
Dulbecco’s Modified Eagle Medium/high glucose medium 
supplemented with 10% fetal bovine serum. The SK-BR-3 
cell line was cultured in RPMI 1640 with 10 mM HEPES 
and 10% fetal bovine serum. Cells were incubated with 5% 
CO2 at 37°C in a humidified incubator.
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Cell viability
Cell viability was determined using a modified MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) assay. Briefly, cells in exponential growth were 
harvested by trypsinization and seeded at a concentration of 
2 × 104 cells/well into 96-well plates, and incubated overnight 
to allow for attachment. The medium was then removed, 
and fresh medium along with graded concentrations of 
antitumor drugs were added to cultures. Following treatment 
(8–48 hours), the MTT solution was added to each well at a 
final concentration of 0.5 mg/mL. After incubation for 3 hours 
at 37°C in the dark, absorbance was measured at 570 nm using 
a multiwell plate reader. For each treatment, cell viability was 
evaluated as a percentage using the following equation: (A570 
of drug-treated sample/A570 of untreated sample) × 100. Data 
presented summarize the mean (± standard deviation) of three 
independent experiments performed in triplicate.
Results and discussion
Assembly of paclitaxel nanoparticles
No method has been established to assemble HDL-like nano-
particles that are responsive to pH.10,11,20,21 Nearly all HDL-like 
nanoparticles contain phospholipids, cholesterol, and choles-
teryl esters, as well as the lipophilic drug of   interest. Because 
phospholipids such as phosphatidylcholine are important 
to apolipoprotein A-I binding, which belts the edge of the 
discoidal nanostructure, we hypothesized that exclusion of 
phospholipids from the nanoparticle might result in sensitivity 
to environmental changes, such as pH (Figure 1). To test this 
hypothesis, we prepared two forms of paclitaxel-containing 
nanoparticles using apolipoprotein A-I, ie, PTX-PL-NP that 
contains both paclitaxel and phosphatidylcholine, and pacli-
taxel nanoparticles that contains only paclitaxel.
PTX-PL-NP could easily be generated by following a 
widely employed procedure with slight modification.21–24 
After equal moles of paclitaxel and POPC were mixed 
together in the presence of 100 mM sodium cholate, the 
detergent was removed either by dilution or dialysis and 
apolipoprotein A-I was added at the time of dilution or 
dialysis. After removing protein and paclitaxel precipitates 
by centrifugation, the supernatant was subjected to separation 
by size exclusion chromatography. This procedure resulted 
in a PTX-PL-NP recovery yield of 50%–60%.
However, in contrast with the formation of PTX-PL-NP, 
which contained phospholipids,20,21 paclitaxel nanoparticles 
lacking phospholipids was not formed either by dialysis 
or dilution (Table 1). Even though apolipoprotein A-I is 
highly soluble in aqueous medium, it unexpectedly coag-
gregated with paclitaxel upon removal of sodium cholate. 
Therefore, a method of simple dilution following heating 
was used. This approach was chosen because it produced 
the highest   assembly yield in the reconstitution of coenzyme 
Paclitaxel PTX-NP at pH 7.4 TEM image
of PTX-NP 
Acidic pH around tumor 
cell or in endosome
apoA-I Paclitaxel
Figure 1 Schematic representation depicting pH-responsive disassembly of paclitaxel nanoparticles, which results in release of paclitaxel under the acid conditions of the 
tumor surroundings or in endosomes.
Abbreviations: PTX-NP, paclitaxel nanoparticles; apoA-I, apolipoprotein A-I; TEM, transmission electron microscopy.
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Q10 nanoparticles (CoQ10-NP).19 When paclitaxel was 
assembled with apolipoprotein A-I (initial apolipoprotein A-I 
to paclitaxel ratio, 1:100) using the same procedure as used 
for CoQ10-NP, including heating at 60°C for emulsification 
with sodium cholate, we obtained soluble paclitaxel nanopar-
ticles with an assembly yield of 0.22. However, this assembly 
yield was much lower than that of CoQ10-NP (0.78). This 
poor assembly yield is likely attributable to incomplete 
heat emulsification due to the high melting temperature of 
paclitaxel (213°C) compared with the relatively low melting 
temperature of CoQ10 (48°C).
Because it has been reported that sonication promotes 
emulsification with detergents when preparing phospholipid 
bilayer vesicles including HDL,25,26 sonication was applied 
instead of heating using 100 mM sodium cholate before the 
assembly of paclitaxel nanoparticles. The resulting assembly 
yield of paclitaxel nanoparticles via sonication was 0.66, 
which was determined after size exclusion chromatography 
purification of the nanoparticles and was three-fold higher 
than that of the heat emulsification method (Table 1). This 
result indicates that the assembly yield is likely related to the 
emulsification yield of paclitaxel with detergent.
The paclitaxel content in the paclitaxel nanoparticles was 
determined to be 62.2% (Table 2). This was much higher 
than the approximately 10% paclitaxel content in the other 
nanoparticles, due to the absence of lipophilic adjuvants 
such as phospholipids, cholesterol, and cholesteryl esters.21 
The molar ratio of apolipoprotein A-I to paclitaxel was 1:55, 
suggesting that about 110 paclitaxel molecules were included 
in each nanoparticle.
Size and shape of paclitaxel nanoparticles
We also prepared several paclitaxel nanoparticles by following 
the same sonication method but by varying the initial mixing 
ratio of apolipoprotein A-I to paclitaxel from 1:50 to 1:200. 
The paclitaxel nanoparticles and PTX-PL-NP were then sub-
jected to size exclusion chromatography and dynamic laser 
light scattering analysis. In the size exclusion chromatography 
analysis, the elution volumes of each nanoparticle were in 
the following order: paclitaxel nanoparticles (initial apoli-
poprotein A-I to paclitaxel, 1:50) .paclitaxel nanoparticles 
(initial apolipoprotein A-I to paclitaxel ratio, 1:100) .PTX-
PL-NP   (initial apolipoprotein A-I to POPC-paclitaxel ratio, 
1:50:50) .paclitaxel nanoparticles (initial apolipoprotein A-I 
to paclitaxel ratio, 1:200, Figure 2A and D). This result was 
consistent with the dynamic laser light scattering analysis. 
While the PTX-PL-NP was 12.2 nm in diameter, the diameters 
of the paclitaxel nanoparticles were determined to be 7.0 nm, 
9.2 nm, and 16.0 nm for paclitaxel nanoparticles (1:50), 
paclitaxel nanoparticles (1:100), and paclitaxel nanoparticles 
(1:200), respectively (Figure 2C–G). These sizes were similar 
to the native HDL found in the liver and recombinant HDL 
particles reconstituted in vitro. This result indicates that the size 
of the paclitaxel nanoparticles can be controlled by adjusting 
the initial mixture ratio of apolipoprotein A-I and paclitaxel. 
All the following experiments were performed using an apo-
lipoprotein A-I to paclitaxel ratio of 1:100.
Transmission electron microscopic analysis revealed 
that the paclitaxel nanoparticle adopted a spherical shape 
(Figure 3). It did not show a ring shape with a halo-like circle 
at the rim, as was observed for the CoQ10 nanoparticle.19 
  Furthermore, phospholipid nanoparticles which contained 
only POPC as a lipidic constituent adopted the typical ring-
like structure (Figure 3C and D). This structural difference 
was likely due to the absence of phospholipids, and we 
hypothesized that amphipathic molecules, such as phospho-
lipids and CoQ10, thermodynamically stabilized the discoidal 
structure of the HDL-based nanoparticle. Supporting our 
observation, in the reverse cholesterol transport pathway, 
HDL undergoes a structural transition from a discoidal to 
spherical shape upon absorption of nonamphipathic mole-
cules, such as cholesterol and cholesterol esters. The spherical 
shape of the nanoparticle has been known to be an essential 
feature for enhancing drug capacity and stability.21
Table 1 Yield of paclitaxel nanoparticles assembled using different 
methods
Assembly 
method
Initial paclitaxel 
(μg/mL)a
Final paclitaxel 
(μg/mL)b
Yield
Dilution 1400 ND ND
Dialysis 1400 ND ND
Heating +  
dilution
1400 302 0.22
Sonication + 
dilution
1400 924 0.66
Notes:  aConcentration  of  paclitaxel  dissolved  in  the  mixture  solution  before 
detergent removal; bconcentration of paclitaxel that is present in HDL-like paclitaxel 
nanoparticles after size exclusion chromatography purification.
Abbreviation: ND, not detected.
Table 2 Composition of paclitaxel nanoparticles prepared in this 
study
Assembly 
method
Protein  
(μg/mL)a
Paclitaxel  
(μg/mL)b
Paclitaxel 
content (%)
Sonication + 
dilution
560 924 62.2
Notes: aProtein concentration was determined spectrophotometrically at 280 nm 
using the extinction coefficients of apolipoprotein A-I; bthe concentration of paclitaxel 
was determined by high pressure liquid chromatography.
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Absorption spectra for the prepared nanoparticles were 
collected at wavelengths ranging from 200 nm to 350 nm. The 
absorption spectra for ethanol, paclitaxel dissolved in ethanol, 
phospholipid nanoparticles, paclitaxel nanoparticles, and PTX-
PL-NP are shown in Figure 4A. Representative spectra of only 
paclitaxel were calculated by subtracting the appropriate refer-
ence spectrum. The subtraction spectrum for free paclitaxel 
(Figure 4B) was obtained by subtracting the ethanol spectrum 
(black line in Figure 4A) from the paclitaxel spectra dissolved 
in ethanol (red line in Figure 4A). The absorption maximum 
for free paclitaxel appeared at 216 nm. Subtraction spectra for 
paclitaxel nanoparticles and PTX-PL-NP (Figure 4B) were cal-
culated by subtracting the phospholipid nanoparticle spectrum 
(green line in Figure 4A) from paclitaxel nanoparticles (yellow 
line in Figure 4A) and PTX-PL-NP (blue line in Figure 4A) 
spectra, respectively. The absorption maximum of paclitaxel 
included in the nanoparticles was at 231 nm. This 15 nm red-
shift of absorption maximum clearly indicates that the paclitaxel 
molecules were indeed assembled in nanoparticles.
pH-responsiveness of paclitaxel 
nanoparticles
An essential feature of pH-responsive nanoparticles for cancer 
chemotherapy is selective drug release at low pH, with the drug 
stably retained inside the nanoparticle at physiological pH.3,27 
To measure the pH-dependent behavior of the   nanoparticles, 
a static light scattering assay was employed. Because the size 
of free apolipoprotein A-I is much smaller than that of the 
nanoparticle (Figure 2B), uncoating of the apolipoprotein 
A-I shell and release of paclitaxel from nanoparticles can 
be easily detected based on a lowered static light scattering. 
Static light scattering of both nanoparticles was measured for 
6 hours at pH 3.8, 5.5, 6.5, 7.4, 8.0, 9.0, and 10.0 (Figure 5A 
and B). The paclitaxel nanoparticles showed little change in 
light scattering intensity above physiological pH (7.4–10.0). 
However, the light scattering intensity decreased as a function 
of time at an acidic pH range (6.5–3.8), the rate of which is 
strongly dependent on pH (Figure 5A). Very interestingly, 
the PTX-PL-NP was stably maintained over a wide range of 
pH values from pH 3.8–10.0 (Figure 5B). This result clearly 
suggests that only the paclitaxel nanoparticle lacking phos-
pholipids responds to pH and dissembles into paclitaxel and 
free apolipoprotein A-I.
To exclude the possibility that the lowered light scattering 
intensity of the paclitaxel nanoparticles at low pH was due to 
aggregation of nanoparticles rather than release of paclitaxel, 
the solution was analyzed by size exclusion chromatography 
(Figure 5C). If the apolipoprotein A-I shell was uncoated from 
the paclitaxel nanoparticles resulting in release of paclitaxel, 
free apolipoprotein A-I should be present in the solution. 
Conversely, if paclitaxel nanoparticles just aggregated, there 
should be no soluble apolipoprotein A-I in the solution. 
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Figure 2 Size of PTX-NP and PTX-PL-NP. Size exclusion chromatographic analysis of PTX-NP (1:100) and PTX-PL-NP (1:50:50) (A) and free apoA-I (B). (D) Size exclusion 
chromatographic analysis of the sizes of PTX-NPs assembled by mixing different ratios of PTX and apoA-I, for which the ratio is 1:50–1:200. (C, E–G) Dynamic light scattering 
assay of PTX-PL-NP (C) and PTX-NP (E–G) with different PTX to apoA-I ratios.
Abbreviations: PTX-NP, paclitaxel nanoparticles; PTX-PL-NP, paclitaxel-phospholipid nanoparticles; apoA-I, apolipoprotein A-I.
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Figure 3 Transmission electron micrograph images of HDL-like PTX-NP. (A and B) Two representative images of PTX-NP. (C and D) Two representative images of PL-NP.
Note: The scale bars correspond to 20 nm.
Abbreviations: PTX-NP, paclitaxel nanoparticles; PL-NP, phospholipid nanoparticles.
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After the paclitaxel nanoparticles had been incubated for 
5 hours at pH 7.4 or 5.5, the samples were analyzed by size 
exclusion chromatography. Indeed, a free apolipoprotein A-I 
peak appeared after incubation at low pH, while a decrease 
in the paclitaxel nanoparticle peak was observed. In contrast, 
the nanostructure of the paclitaxel nanoparticles incubated at 
physiological pH was stable. This result clearly demonstrates 
that at low pH, the paclitaxel nanoparticle uncoats its apolipo-
protein A-I shell and paclitaxel is selectively released at low 
pH, which was not observed for the PTX-PL-NP.
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The paclitaxel nanoparticle was stable at pH 7–10. In 
this pH range, paclitaxel nanoparticles did not show signifi-
cant light scattering intensity changes at 25°C over 5 days. 
In addition, the paclitaxel nanoparticles were stable over a 
wide range of temperatures (4°C, 25°C, and 37°C, Figure 6), 
whereas liposomes aggregated rapidly, even at 4°C, which is 
in agreement with the findings of a previous study.19 These 
results clearly indicate that the phospholipid-deficient pacli-
taxel nanoparticles underwent pH-dependent disassembly 
only in an acidic pH range, suggesting that they are suitable 
drug carriers for cancer chemotherapy.
Secondary structure of apolipoprotein 
A-I in nanoparticles
The exclusion of phospholipids from the paclitaxel nano-
particles resulted in pH-responsive release of paclitaxel at 
an acidic pH range. In order to verify whether this sensitiv-
ity at acidic pH was attributable to the structural instability 
of apolipoprotein A-I due to the absence of phospholipids 
in the paclitaxel nanoparticles, the secondary structures of 
apolipoprotein A-I in the nanoparticles were analyzed using 
far-ultraviolet circular dichroism. The phospholipid nanopar-
ticle consisting of only apolipoprotein A-I and phospholipid, 
the so-called Nanodisc, was used as a control in this study. 
The circular dichroism spectrum of apolipoprotein A-I in the 
phospholipid nanoparticle showed a broad minimum at 
around 208 nm after subtraction of the phospholipid circular 
dichroism spectrum (Figure 6). At pH 7.4, all circular dichro-
ism spectra of apolipoprotein A-I contained in the paclitaxel 
nanoparticles, PTX-PL-NP, and phospholipid nanoparticles 
were almost the same as those of free apolipoprotein A-I, 
which show double minima at 208 nm and 222 nm typical 
of helical proteins (Figure 7B). In contrast, the spectrum of 
apolipoprotein A-I in the paclitaxel nanoparticles exhibited 
a pronounced minimum at around 200 nm at pH 5.5, which 
indicates a high content of random coils in the protein 
 ( Figure 7A). The spectra of apolipoprotein A-I contained 
in PTX-PL-NP and phospholipid nanoparticles at pH 5.5 
were almost the same as those observed at pH 7.4, clearly 
indicating that phospholipid stabilizes the helical structure of 
apolipoprotein A-I. This finding suggests that the significant 
conformational change of apolipoprotein A-I in the pacli-
taxel nanoparticles was due to the absence of phospholipids, 
which in turn led to the structural sensitivity of the paclitaxel 
nanoparticle prone to uncoating of the apolipoprotein A-I 
shell at acidic pH.
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SR-BI-dependent cytotoxicity 
of paclitaxel NP
The HER-2 (or ErbB2, neu) gene encodes a 185 kDa trans-
membrane glycoprotein, and is overexpressed in about 30% 
of human breast carcinomas.28 HER-2 overexpression in 
breast cancer cells also results in increased resistance to 
antitumor drugs, such as paclitaxel.29–31 Furthermore, it is 
known that apolipoprotein A-I in HDL is recognized by 
SR-BI, which is expressed by most cancer cells. Based on 
HER-2-mediated paclitaxel resistance, we tested whether the 
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antitumoral efficacy of paclitaxel could be enhanced when 
encapsulated into nanoparticles.
Expression of HER2 and SR-BI in breast cancer 
cell lines was measured (Figure 8). Reverse transcrip-
tion polymerase chain reaction analysis revealed strong 
expression of HER2 in SK-BR-3 cells, which are known 
to be HER2-overexpressing cells,32 while MCF-7 breast 
cancer cells exhibited very low HER2 mRNA levels.33 
MDA-MB-231 cells have also been reported to be HER-2 
negative.32,34 Expression of SR-BI in MCF-7 cells was mod-
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est, while SR-BI expression in SK-Br-3 cells was high. 
In contrast, MDA-MB-231 cells did not express SR-BI. 
Expression of SR-BI and HER2 was found to be mutually 
correlated in the three cell lines tested.
When cells were treated with free paclitaxel, the HER2-
overexpressing SK-Br-3 cells were shown to be resistant to 
paclitaxel, while HER-2 negative control MDA-MD-231 cells 
were not (Figure 9), which is consistent with the findings of a 
previous report.34 The effect of the paclitaxel nanoparticles and 
PTX-PL-NP on cell death was quite different from the effect of 
free paclitaxel. The paclitaxel nanoparticles and PTX-PL-NP 
did not induce cell death in MDA-MD-231 cells, which express 
neither SR-BI nor HER2. However, MCF-7 and SK-Br-3 cells 
could be killed well by both nanoparticles. This result suggests 
that the antitumor activity of paclitaxel nanoparticles and PTX-
PL-NP is strongly dependent on the presence of the SR-BI 
receptor. Interestingly, the anticancer effect of the paclitaxel 
nanoparticles was much stronger than that of PTX-PL-NP when 
the cancer cells overexpressed HER2 or SR-BI, as in the case 
of SK-Br-3 cells. We believe this enhanced anticancer effect of 
paclitaxel nanoparticles was derived from the pH-responsive 
release of paclitaxel after endocytosis.
Discussion
As described above, the interstitial microenvironment sur-
rounding the solid tumor is acidic. Thus, a pH-responsive 
drug carrier may selectively release an anticancer drug around 
cancer cells while maintaining a low drug concentration near 
normal cells. Apart from the pH of the tumor environment, the 
pH-responsiveness of a drug carrier is more important when the 
nanoparticles containing a drug are endocytosed into the cell. 
Whether drugs are delivered by cationic lipids, nanoparticles 
(as in the case of HDL-like nanoparticles), or cell type-specific 
delivery agents, the intracellular trafficking of drugs begins in 
early endosomal vesicles. Early endosomes fuse with sorting 
endosomes, which subsequently transfer their contents to late 
endosomes. Late endosomal vesicles are acidified (pH 5–6) 
by membrane-bound proton pump ATPases. Finally, these 
late endosomes fuse with lysosomes, which are further acidi-
fied (pH approximately 4.5). Drugs, whether small chemical 
compounds like paclitaxel, siRNA, or an antibody, are broken 
down in the lysosome by various digestive enzymes. To avoid 
lysosomal degradation, drugs must escape from the endosome 
into the cytosol, where they can act on their targets. As such, 
endosomal escape has been a major barrier for efficient drug 
delivery.35 It is clear that the pH-responsiveness of a drug car-
rier is a crucial factor for endosomal escape of the drug because 
of the low pH of endosomes.
Despite the fact that HDL-based nanoparticles have 
the desired features of antitumor drug carriers, including 
small size, biodegradability, high drug content, and abil-
ity to target cancer cells, they had never been designed for 
pH-responsiveness to release their enclosed drugs in acidic 
pH conditions for cancer chemotherapy. Nearly all HDL-
like nanoparticles reported to date contain phospholipids, 
because phospholipids have been considered an indispens-
able host for a HDL-like nanoparticle, whereby it binds to 
apolipoprotein A-I and promotes the α-helical conformation 
required for stable assembly of HDL.36,39 We also failed to 
assemble paclitaxel nanoparticles in the absence of phospho-
lipids when using the dialysis or dilution method to remove 
sodium cholate spontaneously. After trying several different 
reconstitution procedures, we found that simple dilution fol-
lowing sonication allowed for assembly of soluble paclitaxel 
nanoparticles with a reasonable yield.
The phospholipid-deficient paclitaxel nanoparticles 
exhibited obvious pH responsiveness selectively at an acidic 
pH range. In accordance with our hypothesis, the secondary 
structure of apolipoprotein A-I in the paclitaxel nanoparticles 
was less stable than that in PTX-PL-NP or phospholipid 
nanoparticles, rendering the paclitaxel nanoparticles more 
sensitive to acidic pH, which was clearly due to the absence 
of phospholipids. Furthermore, exclusion of phospholipids 
in the preparation of the paclitaxel nanoparticles dramati-
cally increased their paclitaxel content, because the space 
occupied by phospholipids in other forms of HDL-like 
nanoparticles was replaced with paclitaxel. When no phos-
pholipids were used, the paclitaxel content of the paclitaxel 
nanoparticles (1:100) was 62.2% (w/w). Considering that 
the lipophilic content in native HDL found in the human 
MCF-7 MDA-
MB-231
SK-Br-3
HER2 +− +++
SR-BI +− ++
β-actin
SR-BI
HER2
Figure 8 Reverse transcription polymerase chain reaction analysis of SR-BI and 
HER2 expression in MCF-7, MDA-MB-231, and SK-Br-3 cells.
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liver is   approximately 45%, this homogeneous incorporation 
of paclitaxel into the nanoparticle seems to be close to the 
maximal paclitaxel content.
Conclusion
We generated a pH-responsive nanoparticle containing 
paclitaxel by using apolipoprotein A-I, which is abundant in 
the human body. The paclitaxel nanoparticle was stable at 
neutral and basic pH. It was also stable at temperatures rang-
ing from 4°C to 37°C. The nanoparticle released paclitaxel 
by selectively uncoating the apolipoprotein A-I shell at low 
pH. All of these features are required for nanoparticles to be 
useful in cancer chemotherapy. The pH-dependent release 
of paclitaxel from the paclitaxel nanoparticles at acidic pH 
resulted in enhanced antitumor efficacy. The paclitaxel nano-
particles were more potent in killing HER2-overexpressing 
SK-Br-3 cells, which are known to be resistant to free pacli-
taxel, than the PTX-PL-NP which is not pH-dependent. The 
ability of cancer cells to recognize the apolipoprotein A-I of 
HDL through the SR-BI receptor facilitated uptake of the 
paclitaxel nanoparticles into the cancer cell via endocytosis. 
We suggest that the low pH in the endosomes facilitated 
escape of paclitaxel from the endosome to the cytosol, 
thereby protecting paclitaxel from degradation in the lyso-
some, and leading to enhanced anticancer efficacy.
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